Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

New UK Covid variant may be less likely to cause symptoms, study shows

Thu, 18th Nov 2021 14:52

(Sharecast News) - The fast-spreading variant of Covid-19 recently detected in the UK may be less likely to cause symptoms, the results of new research showed.
According to the study, which was conducted by Imperial College London and Ipsos MORI, the new coronavirus variant, dubbed AY.4.2, two thirds of people infected with it reported "any symptom" against 75% of those infected with the dominant strain in the country, known as AY.4.

Furthermore, just a third of those who became infected with the AY.4.2 subvariant had "classic Covid-19 symptoms" versus half of those sick with AY.4.

Previous studies had pointed to the possibility of AY.4.2 being slightly more contagious than its forebear, but whether it caused more serious symptoms remained unknown.

The study, which had been commissioned by the UK's Department of Health and Social Care, looked at swab samples from 100,000 people in England.

AY.4.2 represented 12% of all new cases of the virus detected between 19 October and 5 November, having doubled in prevalence over the preceding two months.

Nonetheless, in remarks to Science Media Future, Dr. Simon Clarke cautioned that: "The data do not indicate the severity of those symptoms or who they occur in. If these AY.4.2. infections occurred in younger people or in communities where vaccine uptake is relatively high, these factors could account for the observed difference."

He further pointed out that even if it were less able to cause disease, the new subvariant would likely still be more virulent than the variants that had triggered lockdowns in the UK.

Clarke also expressed alarm about the fact that as per the study's results, one in 20 school age children in the UK had already been infected with the coronavirus, although that situation might improve with better vaccine rollout and uptake, and if a second dose were eventually authorised for that age group.

Related Shares

More News
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals In...

3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the Europ...

3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommend...

2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worse...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.